A proactive and efficient intellectual property strategy

TxCell has a leading patent position in the field of cellular therapy based on regulatory T cell (Treg).

TxCell aims to cover both its present needs as well as future developments.

To that effect, TxCell’s intellectual property strategy relies on two key pillars: carefully protect in-house innovation through a dynamic patent filing policy, and closely monitor all the work done on Tregs worldwide to identify relevant in-licensing opportunities.

A wide IP protection across the field of therapeutic Tregs

TxCell currently owns or co-owns 16 patent families that represent more than 150 patents granted in major countries.

TxCell’s patent portfolio also includes patent families licensed (or under option) from Yeda Research and Development Co. Ltd (Weizmann Institute of Science, Rehovot, Israel), from Ospedale San Raffaele (OSR) in Milan, and from the Center for Research in Transplantation and Immunology (CRTI) in Nantes.

Overall, TxCell’s patents cover various populations of Tregs, various production methods for both non-modified and engineered Tregs, as well as a broad range of therapeutic applications in autoimmunity, inflammation and transplantation.